Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
South Africa
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Gtpl9416
2. Isis396443
| Molecular Weight | 7127 g/mol |
|---|---|
| Molecular Formula | C234H340N61O128P17S17 |
| XLogP3 | -14.4 |
| Hydrogen Bond Donor Count | 40 |
| Hydrogen Bond Acceptor Count | 167 |
| Rotatable Bond Count | 176 |
| Exact Mass | 7124.2829700 g/mol |
| Monoisotopic Mass | 7122.2762603 g/mol |
| Topological Polar Surface Area | 2820 Ų |
| Heavy Atom Count | 457 |
| Formal Charge | 0 |
| Complexity | 19100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 72 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41707
Submission : 2025-03-28
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41696
Submission : 2025-04-17
Status : Active
Type : II

NDC Package Code : 71860-396
Start Marketing Date : 2016-12-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT



FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41696
Submission : 2025-04-17
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41707
Submission : 2025-03-28
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 71860-396
Start Marketing Date : 2016-12-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
About the Company : Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle manage...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Apitegromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Muscular Atrophy, Spinal.
Lead Product(s): Apitegromab,Nusinersen Sodium,Risdiplam
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apitegromab,Nusinersen Sodium,Risdiplam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Apitegromab Mechanism in Subjects <2 Years with Spinal Muscular Atrophy
Details : Apitegromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Muscular Atrophy, Spinal.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Reports Promising Results For Higher Dose of Spinraza
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Reports Positive Topline Results For Higher Dose Of Nusinersen in SMA
Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nusinersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Atrophy, Spinal.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRxâ...
Details : Nusinersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Atrophy, Spinal.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Lantesens
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Russia registers domestic generic of Spinraza
Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Lantesens
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase IVProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Biomarker Data Support Potential Benefit of SPINRAZA in Infants
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Biogen
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Royalty Pharma
Deal Size: $1,125.0 million Upfront Cash: $500.0 million
Deal Type: Agreement January 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $1,125.0 million
Deal Type : Agreement
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : $500.0 million
January 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Lead Product(s): Nusinersen Sodium,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Biogen
Deal Size: $51.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration January 04, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nusinersen Sodium,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : $51.0 million
Deal Type : Collaboration
Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : $10.0 million
January 04, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications

24 Sep 2025
// PRESS RELEASE
https://investors.biogen.com/news-releases/news-release-details/biogen-provides-regulatory-update-high-dose-regimen-nusinersen

27 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/27/3106639/0/en/New-Data-for-Nusinersen-Underscore-Biogen-s-Commitment-to-Advancing-Clinical-Research-to-Improve-Outcomes-in-SMA.html

23 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/23/3014181/0/en/FDA-and-EMA-Accept-Applications-for-Higher-Dose-Regimen-of-Nusinersen-in-SMA.html

10 Oct 2024
// PRESS RELEASE
https://investors.biogen.com/news-releases/news-release-details/new-higher-dose-nusinersen-efficacy-and-safety-data-presented

04 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/04/2940411/0/en/Biogen-Announces-Positive-Topline-Results-from-Study-of-Higher-Dose-Regimen-of-Nusinersen-Showing-Significant-Benefit-in-Treatment-of-SMA.html

14 May 2024
// THE PHARMA LETTER
https://www.thepharmaletter.com/article/russia-registers-domestic-generic-of-spinraza
Global Sales Information
Market Place
Reply
20 Mar 2020
Reply
25 Jun 2019
Reply
28 Aug 2018

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-09-11
US Patent Number : 10436802
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1944
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-11

Patent Expiration Date : 2030-06-17
US Patent Number : 9717750
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-2093
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-06-17

Patent Expiration Date : 2036-03-04
US Patent Number : 12013403
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-2094
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-03-04

Patent Expiration Date : 2035-09-11
US Patent Number : 10436802
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1942
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-11

Patent Expiration Date : 2025-12-05
US Patent Number : 10266822
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1944
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-12-05

Patent Expiration Date : 2030-11-24
US Patent Number : 8980853
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1941
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-11-24

Patent Expiration Date : 2030-06-17
US Patent Number : 9717750
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1943
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-06-17

Patent Expiration Date : 2025-12-05
US Patent Number : 10266822
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1942
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-12-05

Patent Expiration Date : 2025-12-05
US Patent Number : 10266822
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1943
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-12-05

Patent Expiration Date : 2034-01-09
US Patent Number : 9926559
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1943
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-01-09

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2030-06-17
Date Granted : 2019-08-20
Brand Name : SPINRAZA
Patent Number : 2765396
Filing Date : 2010-06-17
Strength per Unit : 2.4 mg / ml
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : INTRATHECAL
Patent Expiration Date : 2030-06-17
Date Granted : 2019-08-20

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
77
PharmaCompass offers a list of Nusinersen Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nusinersen Sodium manufacturer or Nusinersen Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nusinersen Sodium manufacturer or Nusinersen Sodium supplier.
PharmaCompass also assists you with knowing the Nusinersen Sodium API Price utilized in the formulation of products. Nusinersen Sodium API Price is not always fixed or binding as the Nusinersen Sodium Price is obtained through a variety of data sources. The Nusinersen Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nusinersen Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nusinersen Sodium, including repackagers and relabelers. The FDA regulates Nusinersen Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nusinersen Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nusinersen Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nusinersen Sodium supplier is an individual or a company that provides Nusinersen Sodium active pharmaceutical ingredient (API) or Nusinersen Sodium finished formulations upon request. The Nusinersen Sodium suppliers may include Nusinersen Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Nusinersen Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nusinersen Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Nusinersen Sodium active pharmaceutical ingredient (API) in detail. Different forms of Nusinersen Sodium DMFs exist exist since differing nations have different regulations, such as Nusinersen Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nusinersen Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Nusinersen Sodium USDMF includes data on Nusinersen Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nusinersen Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nusinersen Sodium suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nusinersen Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nusinersen Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nusinersen Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nusinersen Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nusinersen Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nusinersen Sodium suppliers with NDC on PharmaCompass.
Nusinersen Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nusinersen Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nusinersen Sodium GMP manufacturer or Nusinersen Sodium GMP API supplier for your needs.
A Nusinersen Sodium CoA (Certificate of Analysis) is a formal document that attests to Nusinersen Sodium's compliance with Nusinersen Sodium specifications and serves as a tool for batch-level quality control.
Nusinersen Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Nusinersen Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nusinersen Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Nusinersen Sodium EP), Nusinersen Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nusinersen Sodium USP).